MindWalk Signs Multi-Year AI Drug Discovery Agreement With Teva Australia

PUBT · 18h ago
MindWalk Signs Multi-Year AI Drug Discovery Agreement With Teva Australia
  • MindWalk signed a multi-year agreement with Teva Australia to deploy its ReefIQ platform for a defined scope of antibody-discovery work.
  • The recurring-revenue deployment will support discovery decisions using AI-generated predictions to accelerate antibody design optimization.
  • The agreement extends a collaboration that began in 2018.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104971852) on November 04, 2026, and is solely responsible for the information contained therein.